| 3.12 0.24 (8.33%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.76 |
1-year : | 4.39 |
| Resists | First : | 3.22 |
Second : | 3.76 |
| Pivot price | 2.71 |
|||
| Supports | First : | 2.77 |
Second : | 2.49 |
| MAs | MA(5) : | 2.79 |
MA(20) : | 2.72 |
| MA(100) : | 2.89  |
MA(250) : | 3.45 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 57.5 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 6.32 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABSI ] has closed above the upper band by 21.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.23 - 3.24 | 3.24 - 3.26 |
| Low: | 2.87 - 2.88 | 2.88 - 2.89 |
| Close: | 3.1 - 3.12 | 3.12 - 3.14 |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Wed, 16 Jul 2025
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $7 to $13 - 富途牛牛
Mon, 14 Jul 2025
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Fri, 11 Jul 2025
Why Absci's AI-Driven Biotech Play Could Be the Next Breakout - AInvest
Fri, 11 Jul 2025
Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target - Insider Monkey
Mon, 07 Jul 2025
Absci Appoints Biopharma Leader Mary Szela to Board of Directors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 1.1025e+008 (%) |
| Held by Institutions | 10.8 (%) |
| Shares Short | 22,920 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.867e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 351.9 % |
| Return on Equity (ttm) | -27.6 % |
| Qtrly Rev. Growth | 4.82e+006 % |
| Gross Profit (p.s.) | 15.12 |
| Sales Per Share | -23.66 |
| EBITDA (p.s.) | -2.98406e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 4.13 |
| Dividend | 0 |
| Forward Dividend | 2.61e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|